IP Library Granted Patent US 8,119,753
Granted Patent B2
US 8,119,753 · App. 12/242,955 · Granted Feb 21, 2012

Silicone hydrogels with amino surface groups

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,119,753
App. No.
12/242,955
Granted
Feb 21, 2012
Kind
B2
Abstract

A silicone hydrogel comprising monomeric units of one or more amino monomers, wherein the amino monomers are of formula IA, IB, IIA or IIB and monomeric units of one or more silicone monomers wherein R 1 , R 2 and R 3 are independently selected from hydrogen, C 1 -C 6 alkyl or CH 2 OH; R 4 is a C 1 -C 10 alkyl optionally substituted with hydroxyl or carboxylic acid; E is a polymerizable group; X is an anion suitable for quaternary nitrogen; and n is 0, 1, 2, or 3 and m is an integer from 1 to 8.

Claims (21)

1. A silicone hydrogel comprising monomeric units of one or more amino monomers, wherein the amino monomers are of formula IA, IB, IIA or IIB

wherein R 1 , R 2 and R 3 are independently selected from hydrogen, C 1 -C 6 alkyl or CH 2 OH;

R 4 is a C 1 -C 10 alkyl optionally substituted with hydroxyl or carboxylic acid;

E is a polymerizable group;

X is an anion suitable for quaternary nitrogen; and n is 0, 1, 2, or 3 and m is an integer from 1 to 8 and monomeric units of one or more silicone monomers of formula P-Q-P, wherein

j, k and m are independent integers from 1 to 6, 1is an integer from 2 to 10 and m is an integer from 4 to 50; and

R 1 is an aliphatic diradical selected from C 2 -C 10 alkylene, alkylene with an in-chain C 5 -C 6 cycloalkyl, or alkylene with an in-chain phenyl.

2. The silicone hydrogel of claim 1 wherein the monomeric units of amino monomers is selected from the group consisting of dimethylaminoethyl (meth)acrylate, diethylaminoethyl (meth)acrylate, diisopropylaminoethyl (meth)acrylate, dibutylaminoethyl (meth)acrylate, dimethylaminobutyl (meth)acrylate, diethylaminohexyl (meth)acrylate, t-butylaminoethyl (meth)acrylate, isobutylamino-butyl (meth)acrylate, isobutylamino-propyl (meth)acrylate, isobutylamino-ethyl (meth)acrylate, octylamino-ethyl (meth)acrylate isohexylaminoethyl (meth)acrylate, (N-propyl-N-methyl) amino-ethyl (meth)acrylate, t-butylamino-ethyl vinyl acetate, t-butylamino-ethyl crotonate, t-butylamino-ethyl isocrotonate, N,N-dimethylamino-ethyl crotonate, N,N-diethylamino-ethyl isocrotonatc, and the quaternization products of each of these compounds.

3. The silicone hydrogel of claim 1 further comprising monomeric units of one or more hydrophilic monomers.

4. The silicone hydrogel of claim 3 wherein the monomeric units of the hydrophilic monomers is selected from the group consisting of N,N-dimethyl acrylamide, 2-hydroxyethyl methacrylate, glycerol methacrylate, 2-hydroxyethyl methacrylamide and N-vinylpyrrolidone.

5. The silicone hydrogel of claim 1 further comprising one or more high molecular weight hydrophilic polymers selected from the group consisting of poly-N-vinyl pyrrolidone, poly-N-vinyl-2-piperidone, poly-N-vinyl-2-caprolactam, poly-N-vinyl-3-methyl-2-caprolactam, poly-N-vinyl-3-methyl-2-piperidone, poly-N-vinyl-4-methyl-2-piperidone, poly-N-vinyl-4-methyl-2-caprolactam, poly-N-vinyl-3-ethyl-2-pyrrolidone,and poly-N-vinyl4,5-dimethyl-2-pyrrolidone, polyvinylimidazole and poly-N-N-dimethylacrylamide.

6. A silicon hydrogel contact lens comprising a silicon hydrogel lens material with a hydrophilic surface coating, wherein the surface coating is covalently attached to the hydrogel lens material through amido linkages between amino groups on the surface of the hydrogel lens and epoxy groups or carboxylate groups of hydrophilic polymer or hydrophilic copolymer of the hydrophilic surface coating, said amino groups provided by the polymerization of amino monomers

of formula IA, IB, IIA or IIB

wherein R 1 , R 2 and R 3 are independently selected from hydrogen, C 1 -C 6 alkyl or CH 2 OH;

R 4 is a C 1 -C 10 alkyl optionally substituted with hydroxyl or carboxylic acid;

E is a polymerizable group;

X is an anion suitable for quaternary nitrogen; and n is 0, 1, 2, or 3 and m is an integer from 1 to 8 with monomeric units of one or more silicone monomers of formula P-Q-P, wherein

j, k and m are independent integers from 1 to 6, 1 is an integer from 2 to 10 and m is an integer from 4 to 50; and

R 1 is an aliphatic diradical selected from C 2 -C 10 alkylene, alkylene with an in-chain C 5 -C 6 cycloalkyl, or alkylene with an in-chain phenyl.

7. The silicone hydrogel lens of claim 6 wherein the monomeric units of amino monomers is selected from the group consisting of dimethylaminoethyl (meth)acrylate, diethylaminoethyl (meth)acrylate, diisopropylaminoethyl (meth)acrylate, dibutylaminoethyl (meth)acrylate, dimethylaminobutyl (meth)acrylate, diethylaminohexyl (meth)acrylate, t-butylaminoethyl (meth)acrylate, isobutylamino-butyl (meth)acrylate, isobutylamino-propyl (meth)acrylate, isobutylamino-ethyl (meth)acrylate, octylamino-ethyl (meth)acrylate isohexylaminoethyl (meth)acrylate, (N-propyl-N-methyl) amino-ethyl (meth)acrylate, t-butylamino-ethyl vinyl acetate, t-butylamino-ethyl crotonate, t-butylamino-ethyl isocrotonate, N,N-dimethylamino-ethyl crotonate, N,N-diethylamino-ethyl isocrotonate, and the quatemization products of each of these compounds.

8. The silicone hydrogel lens of claim 7 wherein the silicon hydrogel lens material comprises monomeric units of one or more hydrophilic monomers selected from the group consisting of N,N-dimethyl acrylamide, 2-hydroxyethyl methacrylate, glycerol methacrylate, 2-hydroxyethyl methacrylamide and N-vinylpyrrolidone.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Sep 4, 2013
From: BAUSCH & LOMB INCORPORATED
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 031156/0508 →
RELEASE OF SECURITY INTEREST Recorded Aug 13, 2013
From: CITIBANK N.A., AS ADMINISTRATIVE AGENT
To: WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.); BAUSCH & LOMB INCORPORATED; ISTA PHARMACEUTICALS
Reel/Frame 030995/0444 →
SECURITY AGREEMENT Recorded Aug 6, 2012
From: BAUSCH & LOMB INCORPORATED; EYEONICS, INC.
To: CITIBANK N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 028728/0645 →
RELEASE OF SECURITY INTEREST Recorded Aug 5, 2012
From: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 028726/0142 →
SECURITY AGREEMENT Recorded Apr 23, 2012
From: BAUSCH & LOMB INCORPORATED
To: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH
Reel/Frame 028090/0019 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 1, 2008
From: LAI, YU-CHIN; LANG, WEIHONG
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 021613/0231 →